Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease

Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO. Primary endpoints will includeneuropsychological assessments (CDR-SB, iADRS)andblood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported...

the United States, 13/06/2025 (informazione.news - comunicati stampa - salute e benessere)

Primary endpoints will include and , supported by , , and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025 , with trial initiation expected in April 2026, conducted by Syneos Health CRO.

With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer's disease.

Merry Life Biomedical is a Taiwan -based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs.

Media Contact
Dr. Ih-Jen Su
Merry Life Biomedical Company, Ltd.
Phone: +886-910-902-296
Email: suihjen0704@stust.edu.tw 

Logo - https://mma.prnewswire.com/media/2708243/Merry_Life_LOGO_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/merry-life-launches-global-phase-ii-trial-of-tml-6-the-first-drug-targeted-at-autolysosome-pathway-for-therapy-of-alzheimers-disease-302478755.html